No Data
No Data
ACADIA Pharmaceuticals | 10-Q: Quarterly report
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2024 Earnings Call Transcript
ACADIA Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
ACADIA Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Citigroup Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $30
Citigroup analyst David Hoang maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $30.19 to $30.
Earnings Call Summary | ACADIA Pharmaceuticals(ACAD.US) Q1 2024 Earnings Conference
The following is a summary of the ACADIA Pharmaceuticals Inc. (ACAD) Q1 2024 Earnings Call Transcript:Financial Performance:ACADIA Pharmaceuticals reported Q1 revenue of $205.8 million, a 74% increase
Express News | ACADIA Pharmaceuticals Shares Are Trading Lower Following Worse-than-expected Q1 Financial Results